United Therapeutics (UTHR) Tops Q2 EPS by 67c
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $497.27 -0.24%
EPS Growth %: -10.1%
Financial Fact:
Net income per diluted common share (in dollars per share): 3.5
Today's EPS Names:
ALZN, ASPU, USAU, More
EPS Growth %: -10.1%
Financial Fact:
Net income per diluted common share (in dollars per share): 3.5
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $5.24, $0.67 better than the analyst estimate of $4.57. Revenue for the quarter came in at $596.5 million versus the consensus estimate of $524.18 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s said to plan value strategy overhaul to revive US sales growth
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Piper Sandler Reiterates Overweight Rating on Block Inc. (XYZ)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
